Salubris

Shenzhen Salubris Pharmaceuticals Co., Ltd. was listed on the Shenzhen Stock Exchange in 2009 (stock code: 002294). It is a comprehensive pharmaceutical group integrating R&D, production, and sales of pharmaceutical products. In 2016, its operating revenue reached 3.8 billion yuan, with a market value exceeding 35 billion yuan, ranking among the top domestic pharmaceutical industrial enterprises. The company has been honored as one of the "Top 20 Competitive Listed Pharmaceutical Companies in China" and one of the "Top 10 Valuable Listed Companies on the SME Board". We focus on cardiovascular and cerebrovascular diseases, hypoglycemia, anti-tumor, and orthopedics, concentrating on three main business lines: high-end chemical drugs, innovative biopharmaceuticals, and medical devices, while maintaining a leading position in the cardiovascular and cerebrovascular field. We precisely lay out the global industrial chain, covering business in more than 30 countries and regions, including the United States, Germany, France, Japan, etc.
We have strong R&D capabilities, with a research team of over 600 elite members at home and abroad. R&D investment is expected to exceed 600 million yuan in 2017. The company owns numerous proprietary products, such as the Class 1.1 innovative antihypertensive drug "Salubridan" and the Class 3.1 marketed chemical drug "Taijianing", among other high-end prescription drugs. We are the only domestic enterprise whose clopidogrel preparations and raw materials have passed EU certification, and Tajia is marketed in over ten EU countries.
Salubris will continue to optimize and improve its professional academic promotion team, adhering to the corporate philosophy of "patient-centered", establishing itself in the cardiovascular and cerebrovascular field, creating value for customers, and enabling employees to realize their value.